Clinically and statistically significant improvements seen in all subscale scores of KOOS, HOOS questionnaires

TUESDAY, Dec. 5, 2023 (HealthDay News) -- For patients with knee or hip osteoarthritis, glucosamine (GA) combined with chondroitin sulfate (CS) is associated with a reduction in pain and improved joint function and quality of life (QOL), according to a study published online June 18 in the World Journal of Orthopedics.

Alexander M. Lila, M.D., Ph.D., from the Research Institute of Rheumatology Named after VA Nasonova in Moscow, and colleagues examined the impact of GA + CS on clinical outcomes in a prospective study including 1,102 patients with knee or hip osteoarthritis (Kellgren-Lawrence grades I to III) from 51 clinical centers. Changes in outcomes were assessed during 54 to 64 weeks.

The researchers identified clinically and statistically significant improvements in all subscale scores (Pain, Symptoms, Function, and QOL) of the Knee Injury and Osteoarthritis Outcome Score (KOOS) and Hip Disability and Osteoarthritis Outcome Score (HOOS) questionnaires. From baseline to the end of week 64, the mean score increases were 22.87, 20.78, 16.60, and 24.87 on the Pain, Symptoms, Physical Function, and QOL subscales, respectively, for patients with knee osteoarthritis. The corresponding mean score increases were 22.81, 19.93, 18.77, and 22.71, respectively, for patients with hip osteoarthritis. At the end of the observation period, there was a reduction in the number of patients using any nonsteroidal anti-inflammatory drugs (43.1 to 13.5 percent).

 

“This study will contribute to the enhancement of guidelines for the treatment of OA [osteoarthritis] and improve the long-term outcomes for patients with OA,” the authors write.